{rfName}
Au

Indexed in

License and use

Citations

22

Altmetrics

Analysis of institutional authors

Olivas, IAuthorRodriguez-Tajes, SrAuthorLondono, McCorresponding Author
Share
Publications
>
Review

Autoimmune hepatitis: Challenges and novelties

Publicated to:Medicina Clinica. 159 (6): 289-298 - 2022-09-23 159(6), DOI: 10.1016/j.medcli.2022.04.004

Authors: Olivas, Ignasi; Rodriguez -Tajes, Sergio; Londono, Maria Carlota

Affiliations

- Author
Hosp Clin Barcelona, Ctr Invest Biomed Red Enfermedades Hepat & Digest, Serv Hepatol, Inst Invest Biomed August Pi Sunyer IDIBAPS i - Author

Abstract

Autoimmune hepatitis is a chronic inflammatory disease of the liver. The etiology is partly unknown and commonly affects women of all ages. It is characterized by increase in transaminase and immuno-globulin G levels, autoantibodies, and portal inflammatory infiltrate with interface hepatitis in the liver biopsy. The treatment is based on the combination of corticoids and azathioprine, but 20-40% of patients require second-or third-line therapies due to intolerance or insufficient response. Here, we will revise the most important aspects regarding the diagnosis and treatment of autoimmune hepatitis emphasizing the challenges faced in clinical practice.(c) 2022 Elsevier Espana, S.L.U. All rights reserved.

Keywords
2nd-lineAcute autoimmune hepatitisAntibodiesAnticuerposAutoantibodiesAutoimmune hepatitisAzathioprineCorticosteroidsCyclosporineDaño hepático por fármacosDifficultDrug-induced liver injuryEfficacyFemaleHepatitis autoinmuneHepatitis autoinmune agudaHepatitis, autoimmuneHumansImmunoglobulin gImmunosuppressive agentsIntolerantManagementMycophenolate-mofetilTacrolimusTherapyTransaminasesTratamientoTreatment

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Medicina Clinica due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2022, it was in position 58/169, thus managing to position itself as a Q2 (Segundo Cuartil), in the category Medicine, General & Internal. Notably, the journal is positioned en el Cuartil Q3 para la agencia Scopus (SJR) en la categoría Medicine (Miscellaneous).

From a relative perspective, and based on the normalized impact indicator calculated from World Citations from Scopus Elsevier, it yields a value for the Field-Weighted Citation Impact from the Scopus agency: 1.22, which indicates that, compared to works in the same discipline and in the same year of publication, it ranks as a work cited above average. (source consulted: ESI Nov 14, 2024)

This information is reinforced by other indicators of the same type, which, although dynamic over time and dependent on the set of average global citations at the time of their calculation, consistently position the work at some point among the top 50% most cited in its field:

  • Field Citation Ratio (FCR) from Dimensions: 5.32 (source consulted: Dimensions May 2025)

Specifically, and according to different indexing agencies, this work has accumulated citations as of 2025-05-19, the following number of citations:

  • WoS: 7
  • Scopus: 11
  • Europe PMC: 4
  • OpenCitations: 4
Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2025-05-19:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 33.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 43 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.5.
  • The number of mentions on the social network X (formerly Twitter): 3 (Altmetric).
Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Olivas Alberch, Ignasi) and Last Author (Londoño Hurtado, María Carlota).

the author responsible for correspondence tasks has been Londoño Hurtado, María Carlota.